HeartWare, a Framingham, Massachusetts maker of an innovative left ventricular assist system, released results of a European trial testing the survival rates in patients who’ve been implanted with the device. Just like other ventricular assist systems, HeartWare® is designed to provide a bridge to heart transplantation.
Our friends over at MassDevice report on the findings:
Data collected from a 50-patient trial aimed at winning CE Mark approval in the European Union (which was granted in January) showed a six-month survival rate of 90 percent, according to a regulatory filing. Two years after implantation the survival rate was 84 percent. Patients 60 years and older had a survival rate of 93 percent.
The study also showed an 80 percent reduction in post-implantation re-hospitalizations in the 12 months after the procedure, compared with the 12 months preceding implantation.
More from MassDevice…
Link: HeartWare regulatory filings at the SEC…
Product page: HeartWare® Ventricular Assist System…
Flashback: Medical Heart Pumps from HeartWare: HVAD, MVAD and PedVAD